-
Mashup Score: 3
Eli Lilly plans to complete its application for FDA approval of tirzepatide in the coming weeks and expects regulatory action as early as later this year.
Source: CNBCCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: Eli Lilly and CompanyCategories: Cardiologists, Latest HeadlinesTweet-
#Tirzepatide weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2. I guess that they will focus first on diabetologists then they will observe that it will be prescribed by …cardiologists as #GLP1RA🤔. Errare humanum est… https://t.co/NciD1WH2tl
-
-
Mashup Score: 0
More than one-third of adults receiving tirzepatide in clinical trials experience gastrointestinal adverse events, but adverse events leading to drug discontinuation were rare, according to study data. In an article published in the Journal of the Endocrine Society, researchers conducted a systematic review and meta-analysis of clinical trials that reported adverse events related to tirzepatide
Source: www.healio.comCategories: Endocrinology, Latest HeadlinesTweet-
ICYMI: "These findings increase awareness regarding the common as well as rare adverse events associated with different doses of #tirzepatide."@Rahulmishrambbs @DrRishi_raj @SirIsain @stanlakshmi @PriyankaMajety @DineshEdem @drricardocorrea https://t.co/9L0IXhsUpA
-
-
Mashup Score: 0Physicians Struggle to Help Diabetes Patients Get Tirzepatide - 1 year(s) ago
Popular drug faces supply problems and increased demand
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet-
"I get up every morning and I look at patient messages and half of them are due to #Mounjaro." -- @DrKarlNadolsky, of @HollandHospital, on the shortage of the #diabetes drug #tirzepatide. https://t.co/40jXoKNZM4 @MedPageEndo @SophNaama
-
-
Mashup Score: 2
Recent shortages of the type 2 diabetes therapies semaglutide and tirzepatide, widely reported in the consumer press, appear to be resolving, according to manufacturers and prescribers. Beginning in the middle of last year in the United States, but extending globally, the shortages caused numerous challenges for prescribers treating people with type 2 diabetes and with obesity.
Source: www.healio.comCategories: Endocrinology, Latest HeadlinesTweet-
The recent shortages of both #semaglutide and #tirzepatide have led to significant challenges both for prescribers and patients in treating #diabetes and #obesity. @askdrfatima @RodolfoJGalindo @drard https://t.co/R0oiae1kBu
-
-
Mashup Score: 0Tirzepatide: A novel obesity drug ushers in a new era of weight loss — because this one works - 1 year(s) ago
Scientists are still figuring out why tirzepatide causes weight loss. One theory is that they “accidentally” created a new hormone.
Source: Big ThinkCategories: Healthcare Professionals, Latest HeadlinesTweet-
#Tirzepatide : A novel obesity drug is only currently @fda approved for the treatment of #diabetes but has the best weight loss results for #obesity and will be the hormone injectable of choice - Big Think https://t.co/zsTqyDl8tz
-
-
Mashup Score: 1Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue - PubMed - 1 year(s) ago
These findings suggest that tirzepatide induces a thermogenic-like amino acid profile in BAT, an effect that may account for reduced systemic levels of BCAAs in obese IR mice.
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet-
#Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue. https://t.co/GKWVCfj2cM
-
-
Mashup Score: 0
The field of cardiology has seen stunning advances in the past several years: HF, dyslipidemia and cardiomyopathy are just three of the disorders in which there have been recent practice-changing therapeutic innovations. Unfortunately, many cardiologists find themselves inadequately prepared when novel treatments hit the market. Nonetheless, physicians are routinely asked to immediately and
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
The inaugural Pipeline Pulse column by @SethJBaumMD appears in our January issue, online now. Learn more about #tirzepatide, #ziltivekimab and #obicetrapib https://t.co/pQVt4wfyXq #CardioTwitter #Cardiology @LillyPad @novonordiskus @NewAmsPharma
-
-
Mashup Score: 0
Both Eli Lilly and Novo Nordisk scramble to rectify supply shortages
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet-
In May, MedPage Today reported on the FDA approval of the first-in-class #tirzepatide (#Mounjaro) for #type2diabetes. In this report, Kristen Monaco follows up on what's happened since this approval and what's next: https://t.co/0eZzecEhwg @MedPageEndo
-
-
Mashup Score: 0
Our analysis suggests that in people with type 2 diabetes and high cardiovascular risk, tirzepatide slowed the rate of eGFR decline and reduced UACR in clinically meaningful ways compared with insulin glargine.
Categories: Endocrinology, Latest HeadlinesTweet-
Effects of #tirzepatide versus insulin glargine on #kidney outcomes in type 2 #diabetes in the #SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial https://t.co/rpdGCOhEiU #T2D #renal
-
Eli Lilly weight loss drug #tirzepatide data released https://t.co/cdGda19KUE